Global Alzheimer’s Disease Epidemiology Market - Strategic Insights and Forecasts (2026-2035)

The Global Alzheimer's Disease Epidemiology Market is anticipated to grow from 72.6 million patients in 2026 to 99.5 million patients by 2035. This represents a Compound Annual Growth Rate (CAGR) of 3.6% over the forecast period, driven by an aging global population and advancements in diagnosis and treatment.

The expansion of aging populations is the strongest epidemiological driver, as disease prevalence significantly increases among older age groups, leading to sustained growth in diagnosed patient populations. Additionally, the adoption of disease-modifying anti-amyloid therapies is a key driver, shifting demand towards earlier diagnosis during mild cognitive impairment and mild dementia stages.

Anti-amyloid therapies are fundamentally shifting treatment demand towards early-stage patient identification, as clinical benefit depends on intervention before extensive neurodegeneration. This necessitates broader deployment of amyloid PET imaging, plasma biomarkers, and specialized cognitive assessment programs to identify eligible patients earlier.

Biomarker-based diagnosis, including amyloid PET imaging and plasma biomarkers, is gaining critical importance as regulators and payers increasingly require evidence of amyloid pathology before therapy initiation. This trend mandates that neurology centers expand their diagnostic and infusion capabilities, along with specialized monitoring and imaging infrastructure, to support treatment adoption.

Healthcare systems are experiencing significant capacity constraints related to neurology specialists, infusion infrastructure, and longitudinal patient monitoring. The emphasis on earlier intervention and stringent regulatory requirements for new therapies are creating a need for stronger integration between diagnostics, therapeutics, and specialty care networks, straining existing resources.

Evolving regulatory activity significantly influences treatment patterns, particularly as approvals for anti-amyloid monoclonal antibodies often require biomarker confirmation and safety surveillance. These requirements compel market participants, including healthcare institutions and providers, to invest in specialized monitoring and imaging infrastructure and enhance diagnostic capabilities to comply and deliver advanced therapies.